2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Gene Editing, Treatment Considerations, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Immunology, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

2996 TNFα drives thromboinflammation through dysregulated megakaryopoiesis and generation of hyperreactive platelets

Joshua Siner, MD, Molly Brakhane, PhD2, Kimsey Platten3, Ei Thanda Tun4, Abigail Ajanel, PhD5, Katrina Ashworth6, Christopher Letson, PhD, BS7, Nina Lasky8, Mary Fulbright9, Thomas J. Girard, PhD10, Craig Morrell, DVM, PhD11, Stephen Oh, MD, PhD12, Jorge Di Paola, MD13
1 Washington University School of Medicine Campus, Saint Louis, Missouri, United States
2 Washington University School of Medicine Campus, Saint Louis, Missouri, United States
3 Washington University School of Medicine Campus, Saint Louis, Missouri, United States
4 University of Rochester, Rochester, New York, United States
5 Washington University School of Medicine Campus, Saint Louis, Missouri, United States
6 Monash University, Clayton, Victoria, Australia
7 Washington University School of Medicine Campus, Saint Louis, Missouri, United States
8 Washington University School of Medicine Campus, Saint Louis, Missouri, United States
9 Washington University School of Medicine Campus, Saint Louis, Missouri, United States
10 Washington University School of Medicine Campus, Saint Louis, Missouri, United States
11 University of Rochester, Rochester, New York, United States
12 Washington University School of Medicine Campus, Saint Louis, Missouri, United States
13 Washington University School of Medicine Campus, Saint Louis, Missouri, United States

Tumor necrosis factor-alpha (TNFα) is a proinflammatory cytokine with pleiotropic functions mediated through two receptors, which can drive competing signaling outcomes including sustained cytokine production or cell death. TNFα signaling has been implicated in platelet hyperreactivity associated with aging, systemic disease and myeloproliferative neoplasms leading to a prothrombotic state and thromboinflammation. Our group has previously shown that TNFα is the primary cytokine responsible for age-dependent platelet hyperreactivity, and recently that TNFα receptors are absent on megakaryocytes (Mks) and megakaryocyte progenitors (MkPs) suggesting that TNFα regulates megakaryopoiesis through hematopoietic stem and progenitor cells (HSPCs). Consistent with this hypothesis using a novel mouse with genetic deletion of Mk TNFαR1/2 did not protect these mice from TNFα-induced platelet hyperreactivity.

In this study we investigate how TNFα alters normal megakaryopoiesis to regulate thromboinflammation. Chronic TNFα exposure (40 ng/g/day for 28 days) induced expansion of HSPCs, MkPs and Mks across hematopoietic tissues including bone marrow, spleen and lung. TNFα promoted megakaryopoiesis through a canonical hierarchical pathway demonstrated by both immunophenotypic profiling (MkPs: CD48high/CD321low) and lineage tracing using the Flk2-Cre; mT/mG reporter mouse model. MkP fate remained tissue-specific, with bone marrow favoring canonical megakaryopoiesis and lung retaining non-canonical MkPs. Notably, TNFα promoted robust splenic extramedullary hematopoiesis characterized by expansion of HSPCs, MkPs, and Mks, leading to splenic enlargement and suggesting a mechanism by which chronic inflammation remodels hematopoietic output toward thromboinflammatory platelet generation. We next investigated whether TNFα-expanded Mks were dedicated solely to thrombopoiesis or broader functions such as immune surveillance/presentation in response to chronic inflammation. Following chronic TNFα, Mks in the lung and spleen demonstrated increased expression of CCR7, and increased MHC-II among lung Mks, raising the possibility that increased HSPC expansion by TNFα leads to increase in total MkP and Mk functional output extending beyond platelet production to generate Mk populations with potential roles in thromboinflammation and immune regulation.

We next sought to define how TNFα mediated regulation of bone marrow HSPC alters megakaryopoiesis. Chronic TNFα did not affect the fraction of actively cycling cells, measured by in vivo EdU assay, or proportion of cells undergoing apoptosis assessed by Annexin/7-AAD staining. To define the transcriptional mechanisms underlying TNFα-driven megakaryocyte reprograming, we performed scRNA sequencing of TNFα treated HSPCs and Mks. TNFα induced a conserved transcriptional program that originated in early progenitors and persisted through mature Mks, characterized by enrichment of hallmark pathways associated with apoptosis, p53 activation and TGFβ signaling. To further establish the impact of TNFα on long term HSCs (LT-HSCs), we sorted LT-HSCs from bone marrow of chronic TNFα treated and control mice and performed bulk RNA sequencing. Chronic TNFα treated LT-HSCs showed a distinct transcription signature with enrichment for matrix metalloproteinase activation and negatively for mitochondrial functions.

Finally, we determined if chronic TNFα exposure altered the functional capability of LT-HSCs using a modified competitive hematopoietic repopulation assay. A single LT-HSC from TNFα treated or vehicle treated CD45.2 was transplanted with a 9-fold excess of competitor cells (CD45.1.) Both groups showed equivalent engraftment (6 out of 10 per group) and maintained similar CD45.2 donor contribution across all HSPCs and MkPs. Therefore, TNFα induced HSPC expansion reflects a functional increase in hematopoietic output rather than an inflammation induced alteration.

In conclusion, our findings identify HSPCs as the critical cell target through which TNFα regulates megakaryopoiesis and likely promotes hyperreactive platelet formation. Chronic TNFα signaling expands HSPCs and MkPs through hierarchal differentiation, establishing a distinct transcriptional signature that persists through MkPs and Mks. Our data reveal a previously unrecognized mechanism whereby chronic inflammation reprograms hematopoietic stem and progenitor cells to generate functionally altered megakaryocytes and contribute to thromboinflammation.

Joshua Siner, MD: Sanofi - Consultancy (Includes expert testimony); GuidePoint Consulting - Consultancy (Includes expert testimony)